Table 4 Subgroup analyses to assess statistical interaction between pre-existing comorbidities and smoking on mortality post-tuberculosis among persons who initiated treatment for RR or M/XDR TB in Georgia, 2009–2017 (N = 591).
Smoking status | Comorbidities status | Post-TB mortality (%) | cHR (95%CI) | Adjusted Model | |
|---|---|---|---|---|---|
aHRa (95%CI) | p-values for the interaction term | ||||
HIV co-infection | |||||
Non-smokers | HIV negative | 9/117 (7.7) | Reference | Reference | 0.8903 |
HIV positive | 1/2 (50.0) | 13.68 (1.63–114.64) | 12.72 (1.41–114.87) | ||
Smokers | HIV negative | 32/399 (8.0) | Reference | Reference | |
HIV positive | 4/18 (22.2) | 4.72 (1.65–13.49) | 4.87 (1.70–13.94) | ||
Hyperglycemia (i.e., pre-diabetes and diabetes combined) | |||||
Non-smokers | No hyperglycemia | 7/74 (9.5) | Reference | Reference | 0.5909 |
Hyperglycemia | 2/33 (6.1) | 0.66 (0.14–3.17) | 0.35 (0.07–1.76) | ||
Smokers | No hyperglycemia | 19/256 (7.4) | Reference | Reference | |
Hyperglycemia | 8/104 (7.7) | 1.00 (0.44–2.29) | 0.81 (0.35–1.88) | ||
Diabetes | |||||
Non-smokers | No diabetes | 7/74 (9.5) | Reference | Reference | 0.3569 |
Pre-diabetes | 2/17 (11.8) | 1.29 (0.27–6.21) | 0.85 (0.15–4.86) | ||
Diabetes | 0/16 (0.0) | NA | NA | ||
Smokers | No diabetes | 19/256 (7.4) | Reference | Reference | |
Pre-diabetes | 4/51 (7.8) | 1.02 (0.35–3.01) | 1.08 (0.36–3.20) | ||
Diabetes | 4/53 (7.6) | 0.98 (0.33–2.88) | 0.64 (0.21–1.94) | ||
Hepatitis C | |||||
Non-smokers | HCV negative | 4/84 (4.8) | Reference | Reference | 0.8911 |
HCV positive | 1/9 (11.1) | 2.55 (0.28–22.86) | 3.43 (0.35–33.69) | ||
Smokers | HCV negative | 15/232 (6.5) | Reference | Reference | |
HCV positive | 11/97 (11.3) | 1.96 (0.90–4.26) | 1.72 (0.79–3.75) | ||
